Determination of cytokine and growth factor levels to assess endothelial dysfunction in reproductive pathologies

Our objective was to evaluate the level of cytokines and growth factors in peripheral blood in women with pregnancy failure, including women with detectable antiphospholipid antibodies (APhA). Eighty-eight women aged 22 to 45 years were examined. The patients were divided into groups: control group included women with physiologically normal pregnancy; the main group consisted of women with a history of one or more cases of miscarriage. The main group was subdivided into subgroups depending on the presence or absence of APhA in blood serum. The APhA-positive subgroup and a history of miscarriage was then subdivided into subgroups with high and low levels as measured by ELISA test. We evaluated the levels of antibodies to cardiolipin and beta2-glycoprotein-I, and the concentrations of cytokines (IL-1b, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12(p70), IL-13, IL-15, IL-17, Eotaxin, bFGF, G-CSF, GM-CSF, IFNg, IP-10, MCP-1 (MCAF), MIP-1a, PDGF-BB, MIP-1b, RANTES, TNFa, VEGF) in their blood serum and plasma samples. Women with a history of miscarriage, either negative or positive for APhA, are at risk, having an increased contents of proinflammatory cytokines in peripheral blood. Moreover, the women with APhA and a history of miscarriage comprise a group at risk for developing preeclampsia, having increased VEGF, IL-6 and IL-8 levels in peripheral blood. AFAs, regardless of their level, may contribute to development of the pathological process, since an imbalance of proand anti-inflammatory cytokines has been shown in women with APhA, due to a decrease in compensatory anti-inflammatory response. Women with a history of miscarriage and AFAs are more susceptible to placental disorders. Determination of a complex of immunological markers enabled us to clarify various pathophysiological pathways of obstetric pathology, including miscarriage of pregnancy. In this regard, the promising approach would be a search for the most significant combinations of proand anti-inflammatory cytokines, growth-promoting and angiogenic factors with both positive and negative regulation.

1. Inadequate fetal growth that requires medical care for the mother (fetal growth restriction): Clinical recommendations. Moscow, 2022. 76 p.

2. Pavlov O.V., Selkov S.A. Placental macrophages. Morphofunctional characteristics and role in the gestational process. St. Petersburg: Eco-Vector, 2018. 223 p.

3. Premature birth: Clinical recommendations. Moscow, 2020. 66 p.

4. Miscarriage: Clinical recommendations. Moscow, 2021. 56 p.

5. Sokolov D.I., Selkov S.A. Immunologic control of placental vascular network formation. St. Petersburg: N-L, 2012. 206 p.

6. Adanacioglu F., Çetin Ç., Tokat G., Adanacıoglu D., Gokmen Karasu A.F., Çetin M.T. Comparison of the effects of GMCSF-containing and traditional culture media on embryo development and pregnancy success rates. RBGO, 2022, Vol. 44, no. 11, pp. 1047-1051.

7. Ahmad S., Hewett P.W., Al-Ani B., Sissaoui S., Fujisawa T., Cudmore M.J., Ahmed A. Autocrine activity of soluble Flt-1 controls endothelial cell function and angiogenesis. Vasc. Cell, 2011, Vol. 3, no. 1, 15. doi: 10.1186/2045-824X-3-15.

8. Alijotas-Reig J., Esteve-Valverde E., Anunciación-Llunell A., Marques-Soares J., Pardos-Gea J., Miró-Mur F. Pathogenesis, diagnosis and management of obstetric antiphospholipid syndrome: a comprehensive review. J. Clin. Med., 2022, Vol. 11, no. 3, 675. doi: 10.3390/jcm11030675.

9. Bagnasco D., Ferrando M., Caminati M., Bragantini A., Puggioni F., Varricchi G., Passalacqua G., Canonica G.W. Targeting Interleukin-5 or Interleukin-5Rα: Safety considerations. Drug Saf., 2017, Vol. 40, no. 7, pp. 559-570.

10. Bardou M., Hadi T., Mace G., Pesant M., Debermont J., Barrichon M., Wendremaire M., Laurent N., Sagot P., Lirussi F. Systemic increase in human maternal circulating CD14+CD16- MCP-1+ monocytes as a marker of labor. Am. J. Obstet. Gynecol. 2014, Vol. 210, no. 1, pp. 70e1-70e9.

11. Barut F., Barut A., Gun B.D., Kandemir N.O., Harma M.I., Harma M., Aktunc E., Ozdamar S.O. Intrauterine growth restriction and placental angiogenesis. Diagn. Pathol., 2010, Vol. 5, 24. doi: 10.1186/1746-1596-5-24.

12. Bender Atik R., Christiansen O.B., Elson J., Kolte A.M., Lewis S., Middeldorp S., Mcheik S., Peramo B., Quenby S., Nielsen H.S., van der Hoorn M.-L., Vermeulen N., Goddijn M. ESHRE guideline: recurrent pregnancy loss: an update in 2022. Hum. Reprod. Open, 2023, Vol. 2023, no. 1, hoad002. doi: 10.1093/hropen/hoad002.

13. Carp H., Cytokines in recurrent miscarriage. Lupus, 2004, Vol. 13, no. 9, pp. 630-634.

14. Chaiworapongsa T., Romero R., Tolosa J.E., Yoshimatsu J., Espinoza J., Kim Y.M., Kim J.C., Bujold E., Kalache K., Edwin S. Elevated monocyte chemotactic protein-1 in amniotic fluid is a risk factor for pregnancy loss. J. Matern. Fetal Neonatal Med., 2002, Vol. 12, no. 3, pp. 159-164.

15. Dougan M., Dranoff G., Dougan S.K. GM-CSF, IL-3, and IL-5 family of cytokines: regulators of inflammation. Immunity, 2019, Vol. 50, no. 4, pp. 796-811.

16. Galazios G., Tsoulou S., Zografou C., Tripsianis G., Koutlaki N., Papazoglou D., Tsikouras P., Maltezos E., Liberis V. The role of cytokines IL-6 and IL-8 in the pathogenesis of spontaneous abortions. J. Matern. Fetal Neonatal Med., 2011, Vol. 24, no. 10, pp. 1283-1285.

17. Gotsch F., Romero R., Friel L., Kusanovic J.P., Espinoza J., Erez O., Than N.G., Mittal P., Edwin S., Yoon B.H., Kim C.J., Mazaki-Tovi S., Chaiworapongsa T., Hassan S.S. CXCL10/IP-10: a missing link between inflammation and anti-angiogenesis in preeclampsia? J. Matern. Fetal Neonatal Med., 2007, Vol. 20, no. 11, pp. 777-792.

18. Hamulyak E.N., Scheres L.J., Marijnen M.C., Goddijn M., Middeldorp S. Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss. Cochrane Database Syst. Rev., 2020, Vol. 5, no. 5, CD012852. doi: 10.1002/14651858.CD012852.pub2.

19. Han C.S., Mulla M.J., Brosens J.J., Chamley L.W., Paidas M.J., Lockwood C.J., Abrahams V.M. Aspirin and heparin effect on basal and antiphospholipid antibody modulation of trophoblast function. Obstet. Gynecol. 2011, Vol. 118, no. 5, pp. 1021-1028.

20. Jonsson Y., Rubèr M., Matthiesen L., Berg G., Nieminen K., Sharma S., Ernerudh J., Ekerfelt C. Cytokine mapping of sera from women with preeclampsia and normal pregnancies. J. Reprod. Immunol., 2006, Vol. 70, no. 1-2, pp. 83-91.

21. Kraus T.A., Sperling R.S., Engel S.M., Lo Y., Kellerman L., Singh T., Loubeau M., Ge Y., Garrido J.L., Rodríguez-García M., Moran T.M. Peripheral blood cytokine profiling during pregnancy and post-partum periods. Am. J. Reprod. Immunol., 2010, Vol. 64, no. 6, pp. 411-426.

22. Ku C.W., Ong L.S., Goh J.P., Allen J., Low L.W., Zhou J., Tan T.C., Lee Y.H. Defects in protective cytokine profiles in spontaneous miscarriage in the first trimester. Fertil. Steril. Sci., 2023, Vol. 4, no. 1, pp. 36-46.

23. Kwiatek M., Geca T., Kwasniewska A. Pro- and anti-inflammatory cytokines in the first trimestercomparison of missed miscarriage and normal pregnancy. Int. J. Environ. Res. Public Health, 2021, Vol. 18, no. 16, 8538. doi: 10.3390/ijerph18168538.

24. Makhseed M., Raghupathy R., Azizieh F., Farhat R., Hassan N., Bandar A. Circulating cytokines and CD30 in normal human pregnancy and recurrent spontaneous abortions. Hum. Reprod., 2000, Vol. 15, no. 9, pp. 2011- 2017.

25. Mayoral Andrade G., Martínez G.V., Pérez-Campos Mayoral L., Hernández-Huerta M.T., Zenteno E., Pérez-Campos Mayoral E., Martínez Cruz M., Martínez Cruz R., Matias-Cervantes C.A., Meraz Cruz N., Díaz C.R., Cruz-Parada E., Pérez-Campos E. Molecules and prostaglandins related to embryo tolerance. Front. Immunol., 2020, Vol. 11, 555414. doi: 10.3389/fimmu.2020.555414.

26. Motedayyen H., Fathi F., Fasihi-Ramandi M., Sabzghabaee A.M., Taheri R.A. Toll-like receptor 4 activation on human amniotic epithelial cells is a risk factor for pregnancy loss. J. Res. Med. Sci., 2019, Vol. 24, 1. doi: 10.4103/jrms.JRMS_463_18.

27. Namli Kalem M., Akgun N., Kalem Z., Bakirarar B., Celik T. Chemokine (C-C motif) ligand-2 (CCL2) and oxidative stress markers in recurrent pregnancy loss and repeated implantation failure. J. Assist. Reprod. Genet., 2017, Vol. 34, no. 11, pp. 1501-1506.

28. Negrini S., Pappalardo F., Murdaca G., Indiveri F., Puppo F. The antiphospholipid syndrome: from pathophysiology to treatment. Clin. Exp. Med., 2017, Vol. 17, no. 3, pp. 257-267.

29. Ozkan S., Vural B., Filiz S., Coştur P., Dalçik H. Placental expression of insulin-like growth factor-I, fibroblast growth factor-basic, and neural cell adhesion molecule in preeclampsia. J. Matern. Fetal Neonatal Med., 2008, Vol. 21, no. 11, pp. 831-838.

30. Pang X.L., Yin T.L., Yan W.J., Li J., He F., Yang J. Molecular detection of uterine innate lymphoid cells in the immunological mouse model of pregnancy loss. Int. Immunopharmacol., 2019, Vol. 68, pp. 1-6.

31. Polari L., Kumar H., Rautava S., Salminen S., Isolauri E. Increase in serum Interleukin-10 does not alleviate pro-inflammatory MCP-1 production in obese pregnancies. Cytokine, 2018, Vol. 108, pp. 67-70.

32. Quao Z.C., Tong M., Bryce E., Guller S., Chamley L.W., Abrahams V.M. Low molecular weight heparin and aspirin exacerbate human endometrial endothelial cell responses to antiphospholipid antibodies. Am. J. Reprod. Immunol., 2018, Vol. 79, no. 1, 10.1111/aji.12785. doi: 10.1111/aji.12785.

33. Raghupathy R., Makhseed M., Azizieh F., Omu A., Gupta M., Farhat R. Cytokine production by maternal lymphocytes during normal human pregnancy and in unexplained recurrent spontaneous abortion. Hum. Reprod., 2000, Vol. 15, no. 3, pp. 713-718.

34. Ren Y., Wang H., Qin H., Yang J., Wang Y., Jiang S., Pan Y. Vascular Endothelial Growth Factor expression in peripheral blood of patients with pregnancy induced hypertension syndrome and its clinical significance. Pak. J. Med. Sci., 2014, Vol. 30, no. 3, pp. 634-637.

35. Salcedo R., Young H.A., Ponce M.L., Ward J.M., Kleinman H.K., Murphy W.J., Oppenheim J.J. Eotaxin (CCL11) induces in vivo angiogenic responses by human CCR3+ endothelial cells. J. Immunol., 2001, Vol. 166, no. 12, pp. 7571-7578.

36. Schreiber K., Radin M., Sciascia S. Current insights in obstetric antiphospholipid syndrome. Curr. Opin. Obstet. Gynecol., Vol. 29, no. 6, pp. 397-403.

37. Sugimoto M., Kondo M., Kamimoto Y., Ikeda T., Cutler A., Mariya A., Anand-Apte B. Changes in VEGFrelated factors are associated with presence of inflammatory factors in carbohydrate metabolism disorders during pregnancy. PLoS One, 2019, Vol. 14, no. 8, e0220650. doi: 10.1371/journal.pone.0220650.

38. Tagoma A., Haller-Kikkatalo K., Roos K., Oras A., Kirss A., Ilonen J., Uibo R. Interleukin-7, T helper 1, and regulatory T-cell activity-related cytokines are increased during the second trimester of healthy pregnancy compared to non-pregnant women. Am. J. Reprod. Immunol., 2019, Vol. 82, no. 6, e13188. doi: 10.1111/aji.13188.

39. Tong M., Abrahams V.M. Immunology of the Placenta. Obstet. Gynecol. Clin. North Am., 2020, Vol. 47, no. 1, pp. 49-63.

40. Toth B., Haufe T., Scholz C., Kuhn C., Friese K., Karamouti M., Makrigiannakis A., Jeschke U. Placental interleukin-15 expression in recurrent miscarriage. Am. J. Reprod. Immunol., 2010, Vol. 64, no. 6, pp. 402-410.

41. Varla-Leftherioti M., Keramitsoglou T., Tsekoura C. The immunobiology of recurrent miscarriage. In: Recurrent Pregnancy Loss. 3rd ed. CRC Press, 2020. pp. 89-98.

42. Viall C.A., Chamley L.W. Histopathology in the placentae of women with antiphospholipid antibodies: A systematic review of the literature. Autoimm. Rev., 2015, Vol. 14, no. 5, pp. 446-471.

43. Wagner M.M., Jukema J.W., Hermes W., Cessie S., Groot C.J.M., Bakker J.A., Lith J.M.M., Bloemenkamp K.W.M. Assessment of novel cardiovascular biomarkers in women with a history of recurrent miscarriage. Pregnancy Hypertens., 2018, Vol. 11, pp. 129-135.

44. Wang W., Sung N, Gilman-Sachs A., Kwak-Kim J. T helper (Th) cell profiles in pregnancy and recurrent pregnancy losses: Th1/Th2/Th9/Th17/Th22/Tfh Cells. Front. Immunol., 2020, Vol. 11, 2025. doi: 10.3389/fimmu.2020.02025.

45. Wang Y., Shi D., Chen L. Lipid profile and cytokines in hypertension of pregnancy: A comparison of preeclampsia therapies. J. Clin. Hypertens. (Greenwich), 2018, Vol. 20, no. 2, pp. 394-399.

46. Wegmann T.G., Lin H., Guilbert L., Mosmann T.R. Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon? Immunol. Today, 1993, Vol. 14, no. 7, pp. 353-356.

47. Yang R., Zhang J., Zhang L., Liu Y., Guo Q. Combined detection of anticardiolipin and anti-beta2- glycoprotein 1 antibodies may predict pregnancy outcome. Am. J. Transl. Res., 2022, Vol. 14, no. 3, pp. 1750-1756.

48. Yang X., Su S., Ren Q., Liu L., Li J., Zhang W., Cai K., Xu Z., Pan X.. BushenHuoxue recipe for the treatment of prethrombotic state of ACA-positive recurrent miscarriage via the regulation of the PI3K-AKT signaling pathway. Evid. Based Complement. Alternat. Med., 2022, Vol. 2022, 2385534. doi: 10.1155/2022/2385534.

49. Yang X., Tian Y., Zheng L., Luu T., Kwak-Kim J. The update immune-regulatory role of pro- and antiinflammatory cytokines in recurrent pregnancy losses. Int. J. Mol. Sci., 2023, Vol. 24, no. 1, 132. doi: 10.3390/ijms24010132.

50. Yockey L.J., Iwasaki A. Interferons and proinflammatory cytokines in pregnancy and fetal development. Immunity, 2018, Vol. 49, no. 3, pp. 397-412.

51. Zeisler H., Llurba E., Chantraine F., Vatish M., Staff A.C., Sennström M., Olovsson M., Brennecke S.P., Stepan H., Allegranza D., Dilba P., Schoedl M., Hund M., Verlohren S. Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. N. Engl. J. Med., 2016, Vol. 374, no. 1, pp. 13-22.